Sanofi (EPA:SAN)
France · Delayed Price · Currency is EUR 87.60
-0.47 (-0.53%)
Oct 31, 2025, 5:35 PM CET
Sanofi Revenue
Sanofi had revenue of 13.17B EUR in the quarter ending September 30, 2025, a decrease of -6.97%. This brings the company's revenue in the last twelve months to 45.93B, down -5.19% year-over-year. In the year 2024, Sanofi had annual revenue of 44.29B with 7.73% growth.
Revenue (ttm)
45.93B
Revenue Growth
-5.19%
P/S Ratio
2.32
Revenue / Employee
554.20K
Employees
82,878
Market Cap
106.59B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 44.29B | 3.18B | 7.73% |
| Dec 31, 2023 | 41.11B | 805.00M | 2.00% |
| Dec 31, 2022 | 40.30B | 1.13B | 2.88% |
| Dec 31, 2021 | 39.18B | 1.81B | 4.83% |
| Dec 31, 2020 | 37.37B | -262.00M | -0.70% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| EssilorLuxottica Société anonyme | 27.24B |
| Eurofins Scientific SE | 7.14B |
| emeis Société anonyme | 5.77B |
| Clariane SE | 5.31B |
| Ramsay Générale de Santé | 5.24B |
| bioMérieux | 4.12B |
| Ipsen | 3.76B |
| Sartorius Stedim Biotech | 2.95B |
Sanofi News
- 4 days ago - Sanofi extends agreement with Medidata on clinical trials - Seeking Alpha
- 4 days ago - Medidata And Sanofi Expand Collaboration To Advance Clinical Research Innovation - Nasdaq
- 4 days ago - UPDATE - Medidata Extends Collaboration with Sanofi for the Development of New Therapies with an Improved Patient Journey - GlobeNewsWire
- 7 days ago - Sanofi Breaks Above 200-Day Moving Average - Bullish for SNY - Nasdaq
- 7 days ago - Sanofi SA (SNY) Q3 2025 Earnings Call Highlights: Strong Growth Driven by DUPIXENT and New Launches - GuruFocus
- 7 days ago - Sanofi: Is Dupixent Too Successful? - Seeking Alpha
- 8 days ago - Q3 2025 Sanofi SA Earnings Call Transcript - GuruFocus
- 8 days ago - Sanofi Q3: Cash-Rich, Cheap, And Loading 2026 Shots On Goal - Seeking Alpha